GM‐CSF showed no clear difference in induction of clinical remission (CDAI < or = 150) compared with placebo (low certainty).
GM‐CSF showed no clear difference in induction of 100‐point clinical response compared with placebo (low certainty).
GM‐CSF showed no clear difference in induction of 70‐point clinical response compared with placebo (low certainty).
GM‐CSF showed no clear difference in adverse events compared with placebo (moderate certainty).
GM‐CSF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
IL‐10 showed no clear difference in complete remission (CDAI<150 with a decrease in CDAI of at least 100… compared with placebo (moderate certainty).
IL‐10 showed no clear difference in clinical remision (CDAI<150) compared with placebo (moderate certainty).
IL‐10 probably leads to higher withdrawls due to adverse events compared with placebo (moderate certainty).
Summary of findings table ‐ Stem Cell showed no clear difference in clinical remission compared with placebo or Control (low certainty).
It is very uncertain whether summary of findings table ‐ Stem Cell changes CDAI <150 at 24 weeks compared with placebo or Control (very low certainty).
Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).
Summary of findings table ‐ Stem Cell may leads to higher fistula closure in long‐term compared with placebo or Control (low certainty).
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
Intensification of prophylactic therapy guided by colonoscopy showed no clear difference in clinical recurrence ( compared with intensification guided by clinical recurrence (low certainty).